Literature DB >> 18929234

Ranolazine: new paradigm for management of myocardial ischemia, myocardial dysfunction, and arrhythmias.

Peter H Stone1.   

Abstract

Ranolazine, which was approved by the US Food and Drug Administration in January 2006, provides a mechanism of action to treat ischemia that has not hitherto been available. Ranolazine is effective in reducing manifestations of ischemia and angina, and it also holds potential promise to be effective in the management of left ventricular dysfunction, particularly diastolic dysfunction, and arrhythmias. This article provides an update on the available studies concerning the value of ranolazine across the spectrum of cardiovascular disease.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18929234     DOI： 10.1016/j.ccl.2008.06.002

Source DB:  PubMed          Journal:  Cardiol Clin        ISSN： 0733-8651            Impact factor:   2.213


  10 in total

1.  Sarcoendoplasmic reticulum Ca(2+) ATPase. A critical target in chlorine inhalation-induced cardiotoxicity.

Authors:  Shama Ahmad; Aftab Ahmad; Tara B Hendry-Hofer; Joan E Loader; William C Claycomb; Olivier Mozziconacci; Christian Schöneich; Nichole Reisdorph; Roger L Powell; Joshua D Chandler; Brian J Day; Livia A Veress; Carl W White
Journal:  Am J Respir Cell Mol Biol       Date:  2015-04       Impact factor: 6.914

Review 2.  Ranolazine: a new approach to treating an old problem.

Authors:  Bharath M Reddy; Howard S Weintraub; Arthur Z Schwartzbard
Journal:  Tex Heart Inst J       Date:  2010

3.  Evolving approaches to the management of heart failure with preserved ejection fraction in patients with coronary artery disease.

Authors:  Sanjiv J Shah
Journal:  Curr Treat Options Cardiovasc Med       Date:  2010-01

4.  Damage to mitochondrial complex I during cardiac ischemia reperfusion injury is reduced indirectly by anti-anginal drug ranolazine.

Authors:  Ashish K Gadicherla; David F Stowe; William E Antholine; Meiying Yang; Amadou K S Camara
Journal:  Biochim Biophys Acta       Date:  2011-12-08

5.  The utility of cardiopulmonary exercise testing in the assessment of suspected microvascular ischemia.

Authors:  Sundeep Chaudhry; Ross Arena; Karlman Wasserman; James E Hansen; Gregory D Lewis; Jonathan Myers; Romualdo Belardinelli; Brian LaBudde; Nicholas Menasco; William E Boden
Journal:  Int J Cardiol       Date:  2009-02-23       Impact factor: 4.164

Review 6.  Medical management of stable coronary atherosclerosis.

Authors:  P Pellicori; P Costanzo; A C Joseph; A Hoye; S L Atkin; J G F Cleland
Journal:  Curr Atheroscler Rep       Date:  2013-04       Impact factor: 5.113

7.  Emerging clinical role of ranolazine in the management of angina.

Authors:  David S Vadnais; Nanette K Wenger
Journal:  Ther Clin Risk Manag       Date:  2010-10-21       Impact factor: 2.423

8.  Effects of ranolazine on exercise capacity, right ventricular indices, and hemodynamic characteristics in pulmonary arterial hypertension: a pilot study.

Authors:  Sadiya S Khan; Michael J Cuttica; Lauren Beussink-Nelson; Anastasia Kozyleva; Cynthia Sanchez; Hamorabi Mkrdichian; Senthil Selvaraj; Jane E Dematte; Daniel C Lee; Sanjiv J Shah
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

9.  Childhood ataxia: clinical features, pathogenesis, key unanswered questions, and future directions.

Authors:  Claire N Ashley; Kelly D Hoang; David R Lynch; Susan L Perlman; Bernard L Maria
Journal:  J Child Neurol       Date:  2012-08-01       Impact factor: 1.987

10.  A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin.

Authors:  Ajay Mishra; Himanshu V Pandya; Nikhil Dave; Mahesh Mathew; Chinmaye M Sapre; Sneha Chaudhary
Journal:  Indian J Pharmacol       Date:  2014 Sep-Oct       Impact factor: 1.200
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.